CS Paper Radar

Revisiting Structure-Based Filtering for AI-Designed Antibodies: Opportunities, Limits, and What Matters

Langzhang Liang, Juncheng Qian, Xiaojie Ma, Mingxi Zou, Yinghui Xu, Zenglin Xu, Tianlei Ying

cs.CE ·submitted 2026-10-16 08:35 UTC · v2

Abstract

AI antibody design can generate far more candidates than can be experimentally tested, making post-generation filtering a central bottleneck. We study whether structure-prediction outputs can help prioritize AI-designed antibodies for experimental validation. We evaluate this problem on 4,184 experimentally characterized antibody-antigen pairs, combining newly generated wet-lab measurements with curated affinity data across diverse antigens and assay settings. We introduce two complementary filtering signals: Regional Interaction Contrast (RIC), which captures support for the predicted antibody-antigen interface, and Non-CDR Antibody Confidence (NAC), which measures antibody confidence outside the CDRs. Across AlphaFold 3, Protenix-v2, and ESMFold2, we find a striking difference in what information matters for filtering. Interface evidence is strongest when comparing candidates designed for different antigens, whereas antibody-level reliability is substantially more informative for ranking candidates within the same antigen. In particular, non-CDR antibody confidence consistently outperforms whole-antibody confidence across predictors, revealing an unexpected source of filtering signal beyond the predicted interface. Finally, we examine the information encoded in the predictor outputs themselves. Predicted structures contain substantial but incomplete binding-related signal, revealing both the opportunities and limits of structure-based filtering: better metrics can exploit current predictors more effectively, but their performance ultimately remains constrained by what those predictors can distinguish.

Comment
29 pages, 4 figures

Closest papers

Nearest neighbours by meaning across the whole index.

Learning Task-Specific Antibody Representations via Function-Aware Masking

cs.LG q-bio.BM ·2026-09-01 ·Ayan Goel, Thomas A. Walton, Amirali Aghazadeh
published similarity 0.61
Abstract · Accepted to MLCB 2026 (Oral)

Antibody-specific language models pretrained via masked language modeling (MLM) learn representations that are critical for downstream sequence design and property prediction tasks. Yet, the corruption process itself is rarely leveraged as a source of inductive bias during pretraining. While preferentially masking complementarity-determining regions (CDRs) improves binding-related predictions, antibodies possess diverse biological priors over a variety of functions. Herein, we introduce function-aware masking, a family of pretraining algorithms that align mask placement with specific functional priors (e.g., from IMGT annotations or structure predictions) to shape the learned representation space. We show that these specialist masking strategies significantly improve performance on their respective objectives, yielding up to a 14% gain on structure-related tasks and up to a 5.9x improvement on CDR-related tasks. To further improve performance across multiple functional axes, we develop hybrid masking strategies that integrate multiple priors, balancing reconstruction over binding, structural, and biophysical objectives. Our results demonstrate that informed mask placement provides a parameter-free mechanism for imposing functional inductive biases in antibody language model training.

0.31

AbGaze: Attentive Geometric Representation Learning for End-to-End Antibody Design

cs.AI ·2026-09-28 ·Jiashuo Wang, Siqi Fan, Yizhen Luo, Zaiqing Nie
similarity 0.60
Abstract

Computational antibody design requires representations that capture the geometric patterns underlying antigen--antibody interactions, yet existing approaches often rely on scalar distances or surface-intrinsic features, leaving cross-molecular geometry largely implicit. We present AbGaze, an end-to-end antibody design framework based on attentive geometric representation learning, which encodes distance, spatial direction, and surface-normal orientation of antigen surfaces relative to antibody-residue local frames, and adaptively aggregates these geometric interactions according to their interfacial context. The learned interaction representation is shared across multi-CDR co-design, complex structure prediction, and affinity optimization, with local-frame geometric supervision further constraining the representation. AbGaze outperforms prior methods across all three tasks: relative to the second-best method, it improves amino-acid recovery by 7.1% and reduces structural error by 14.9% on average over the six CDRs, improves interface docking quality (DockQ) by 6.6%, and raises the affinity improvement rate (IMP) by 32.5%.

0.28

Can agents reliably design therapeutic antibodies?

cs.LG q-bio.QM ·2026-10-31 ·Asli Alpman, Nick Bhattacharya, Aaron Solomon, Hunter Elliott
similarity 0.60
Abstract

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.

0.08

Reasoning in the loop: antibody lead optimization by probing mechanism and measurement

cs.LG cs.AIq-bio.BM ·2026-11-15 ·Samuel Stanton, Aaron Solomon, Emily Delaney, Melanie Montgomery, Crystal Humphries +5 more
similarity 0.58
Abstract · 31 pages, 19 figures, 8 tables

Lab-in-the-loop systems, in which a model proposes molecules, automated assays measure their properties and the results retrain the model, are a popular approach to antibody lead optimization. These systems optimize for a specification defined with metrics computed from instrument signals, so their success depends on how well those metrics serve as proxies for the properties a drug candidate needs. When a metric is a poor proxy, neither a better model nor more data will fix it, and identifying the problem usually requires expert review. We report two campaigns run on BigHat Biosciences' Milliner platform, one on an anti-albumin nanobody (VHH) and one on an anti-mesothelin single-chain variable fragment (scFv), in which a research team and a general-purpose AI agent, Claude, brought scientific reasoning into the loop. Over seven rounds and about 1,010 design variants we built libraries from antibody lineage, structure and biophysics, and found from the raw curves that on each scaffold one thermal metric did not measure what its name implied. The libraries were built as controlled comparisons, so the results also show what each mutation contributes to each property. We fit a physical model of the curves, used it to choose metrics suited to each scaffold, and changed the experimental protocol, varying protein concentration and heating rate, to test the model against pre-registered predictions. Both leads improve on their parents in affinity, thermal stability and aggregation while improving or maintaining yield and purity.

0.27

Multi-Assay Antibody Developability Prediction with Shared Structure-Language Representations

cs.LG q-bio.BM ·2026-11-13 ·Daria B. Kokh
similarity 0.58
Abstract · 27 pages, 11 figures, 4 tables, Supplementary Material

Early assessment of antibody developability is critical in drug discovery, but computational approaches remain limited by the scarcity of experimental data. We explore two strategies for working within that limit. First, we designed per-residue physicochemical descriptors encoding the local structural environment, including new terms such as directional charge asymmetry and screened electrostatic potential. These feed a convolutional network, combined with protein language model (PLM) embeddings in a two-stream architecture: the two are encoded and predicted independently and merged only at the prediction stage. Second, a shared trunk with per-assay heads passes information between related assays. Both are implemented in the Multi-Assay Developability Model (MADM) and evaluated on eight assays: HIC, heparin affinity (HAC), AC-SINS, and polyspecificity ELISA against BVP, dsDNA, insulin, ovalbumin and soluble membrane proteins (SMP), with labels from 29 open sources. Structural descriptors match or exceed PLM embeddings (AbLang2, ESM2) on several assays; combining the streams gives a small but consistent gain in accuracy and reduces seed-to-seed variance. Multi-assay training raises Spearman rho for ovalbumin and SMP by about 0.1, where assays correlate and share sequence space. Under cluster-split cross-validation the strongest results are for HAC, ovalbumin, insulin, SMP and HIC (rho = 0.70-0.82); AC-SINS, BVP and dsDNA are weaker (0.50-0.55). In these three, sequence clusters largely coincide with data source, so a held-out fold measures transfer to differently calibrated measurements as well as to new sequences. On the 80-antibody GDPa3 hold-out, performance falls by rho around 0.1 for all but SMP (0.22). Transfer to the VHH panel of Ginkgo GDPa5 gives comparable results, and scFv validation against binary SMP labels yields F1 = 0.89, AUC = 0.95.

0.29

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.58
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates

cs.CE ·2026-10-12 ·Joseph D. Viviano, Almer van der Sloot, Quentin Fournier, Robert M. Vernon, Christopher James Langmead +1 more
similarity 0.58
Abstract · 21 Figures, 14 Tables, Under review

Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent machine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.

0.33

Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19

cs.LG q-bio.BM ·2026-10-23 ·Raghav Paladugu, Fardina Fathmiul Alam
published similarity 0.54
Abstract · Accepted as a short paper at the 2026 IEEE International Conference on Bioinformatics and Biomedicine (BIBM 2026)

Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.

0.40